Back in 2016, when Zika virus first began to cause infections in the Americas, University of Wisconsin–Madison researchers pulled together a coalition of scientists to study the virus and openly … Read more
Our interdisciplinary team of scientists collaborates to develop nanovaccines and nanotherapeutics
We are developing a universal influenza nanovaccine that would be effective against more strains of flu than current flu shots
For cancers, we are researching tumor-specific targets for nanotherapeutics
Nanovaccines can prevent tropical parasitic diseases such as malaria and filarisis
Nanotherapeutics use lower dosages than systemic drugs, allowing life-saving drugs to be used for young children
Nanoparticles can deliver therapeutic agents across the blood-brain barrier to treat neural disorders such as Alzheimer's, Parkinson's, and traumatic brain injury
Nanotechnologies can help optimize aging via improved biosensing capabilities and vaccine delivery
Researching veterinary diseases such as swine flu, avian flu, and bovine respiratory syncytial virus can help design nanovaccines to prevent similar diseases in humans
No needles, no boosters: extended-release nanovaccines can be delivered by nasal inhaler rather than injection
Nanovaccines don't need refrigeration (polio campaign worker in India carrying styrofoam cooler for vaccine)
Nanoparticles average only 300 nanometers in diameter, 1000 times smaller than the period at the end of a sentence.
